Medicine & Life Sciences

1. Lymphoma, Large B-Cell, Diffuse 100%
2. Lymphoma 50%
3. Lenalidomide 46%
4. Rituximab 39%
5. Follicular Lymphoma 37%
6. Non-Hodgkin's Lymphoma 32%
7. Survival 32%
8. Progression-Free Survival 32%
9. B-Cell Lymphoma 30%
10. B-Lymphocytes 21%
11. B-Cell Chronic Lymphocytic Leukemia 20%
12. Therapeutics 16%
13. Hodgkin Disease 15%
14. Clinical Trials 13%
15. Cyclophosphamide 11%
16. Bendamustine Hydrochloride 11%
17. Mantle-Cell Lymphoma 11%
18. Waldenstrom Macroglobulinemia 10%
19. Neoplasms 10%
20. Multiple Myeloma 10%
21. Vincristine 9%
22. Recurrence 9%
23. Confidence Intervals 9%
24. Doxorubicin 9%
25. Monocytes 8%
26. Prednisone 8%
27. Molecular Epidemiology 8%
28. T-Lymphocytes 8%
29. T-Cell Lymphoma 8%
30. Stem Cell Transplantation 7%
31. Drug Therapy 7%
32. Everolimus 7%
33. Germinal Center 7%
34. polatuzumab vedotin 6%
35. Peripheral T-Cell Lymphoma 6%
36. Anthracyclines 6%
37. Biomarkers 6%
38. Cohort Studies 6%
39. Stem Cells 6%
40. Lymphocyte Count 6%
41. Mutation 6%
42. Transplants 6%
43. Radioimmunotherapy 5%
44. ofatumumab 5%
45. Retrospective Studies 5%
46. Chimeric Antigen Receptors 5%
47. Lymphocytes 5%
48. Medical Oncology 5%
49. Neurolymphomatosis 5%
50. Cell- and Tissue-Based Therapy 5%